Vitro Diagnostics (VODG) 0.0420 $VODG
Vitro Biopharma Launches New Products to Advance Breast Cancer Treatment
ACCESSWIRE - Tue May 03, 8:30AM CDT
GOLDEN, CO / ACCESSWIRE / May 3, 2016 / Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the launch of breast cancer CAFs (cancer-associated fibroblasts) that provide additional tools for drug discovery in the quest to eradicate cancer. CAFs reside within tumor tissue and serve various functions including suppression of immune responses to cancerous cells, support of tumor cell growth and enhancement of metastasis. Modern immunotherapy has evolved into CAR-T technology (chimeric antigen receptor T cells) whereby patient's immune cells are genetically engineered to migrate to, attach to and eliminate cancer cells. Several biotech firms are developing CAR-T cancer immunotherapeutic products including Juno Therapeutics, Kite Pharma and Ziopharm Oncology. Some early trials for treatment of leukemia show nearly complete remission using this therapy. However, CAFs present within solid tumors continue to block engineered T cells and require intervention to maximize immunotherapy to completely eradicate cancerous cells (PNAS 110: 20212, 2013).
KITE: 50.91 (-0.18), JUNO: 42.66 (-0.70)
CEO Letter to Shareholders: 2015 Results Expand Therapy Options for Concussion
ACCESSWIRE - Wed Nov 04, 12:13PM CST
GOLDEN, CO / ACCESSWIRE / November 4, 2015 /
Vitro Biopharma Launches New Bioanalytical Services and Novel Stem Cell-Derived Renal & Neural Cells
ACCESSWIRE - Tue Sep 22, 9:19AM CDT
GOLDEN, CO / ACCESSWIRE / September 22, 2015 / Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced expansion of its product/service offerings to include biomarker profiling services and stem cell derived neuronal and renal cells. Vitro Biopharma's new services include simultaneous determination of several molecules through multi-plexed assays. The cells of our bodies communicate with each other through the secretion of numerous bioactive substances that control fundamental physiological and pathological conditions. Our new services offer precise measurement of numerous different signaling molecules at once including cytokines, growth factors, hormones and other biological signaling molecules. We offer panels of biomarkers for analysis of the several organ systems and pathological states of the body: cancer, cardiovascular, immunology/inflammation, metabolism/endocrine, neurology and toxicology. Within each category we offer several panels of individual biomarker groups.
Vitro Biopharma Announces Advancement of its Traumatic Brain Injury Clinical Trial and a Favorable Ruling from the FDA
ACCESSWIRE - Wed Sep 02, 11:41AM CDT
GOLDEN, CO / ACCESSWIRE / September 2, 2015 / Vitro Diagnostics, Inc. (OTC: VODG), dba Vitro Biopharma, announced advances in clinical applications of its products and a favorable ruling by the FDA regarding this trial. The Company's phase I clinical trial consists of combining two previously FDA-approved drugs in a novel manner to treat TBI, including concussion, by regeneration of damaged cells through the activation of resident stem cells within the brain. TBI is a high incidence condition with few therapeutic options besides reduction of secondary injury and rehabilitation or physical therapy. Brain stem cells exist in only restricted parts of the brain but appear to be capable of regenerating cells of the brain when activated by the appropriate biological signal, in this case, a unique combination of drugs previously approved for other indications. While stem cell therapy is often achieved by stem cell transplants, it is also possible to activate stem cells by biological signaling agents that activate specific pathways resulting in stem cell proliferation, differentiation and migration. There are FDA-approved drugs used to stimulate red and white blood cell formation that have been used for decades now to treat patients undergoing chemotherapy and the resulting blood cell deficiencies. Other stem cell activating compounds are known and being developed.
Vitro Biopharma Launches MSC-derived Cardiac and Neural Cells for Pre-clinical Toxicology Testing
ACCESSWIRE - Tue Jun 02, 8:52AM CDT
GOLDEN, CO / ACCESSWIRE / June 2, 2015 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the commercial launch of cardiac and neural cells that are differentiated from human MSCs. Our new products include cardiomyocytes, alpha motor neurons and neural stem cells. In support of this commercial launch, we have also launched an improved and updated website featuring enhanced functionality and improved access to product information. Our newly developed cardiomyocytes and alpha motor neurons compliment existing stem cell-derived cells for use in cell-based assays of drug toxicity: MSC-derived osteoblasts and chondrocytes. Vitro Biopharma has additional cell types in development including dopaminergic neurons, proximal tubule epithelial cells and podocytes. The latter cells will enable cell-based assays for renal toxicity.
Alternatives to Stem Cell Transplants Supported by Key Medical Breakthroughs of 2014
ACCESSWIRE - Tue Jan 13, 9:18AM CST
GOLDEN, CO / ACCESSWIRE / January 13, 2015 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the growing scientific support for use of stem cells that reside within the body for therapeutic and performance enhancement. A key medical advance of 2014 was research published by scientists at Stanford University and Harvard University regarding mechanisms underlying "parabiosis", the well-known reversal of aging when young animal blood is transferred into older animals. This research, considered a key scientific advance of 2014, identified factors in blood that transform stem cells from an inactive, latent form to active cells that regenerate and replenish aging cells resulting in reversal of aging in animals. This newly identified factor, called growth-differentiation factor 11 (GDF11, or, BMP-11) adds to a growing list of endogenous biological agents that activate stem cells from quiescence to growth and differentiation. The well-known growth factors erythropoietin and G-CSF have been used as therapeutic agents for 25 years to treat anemia and immuno-suppression resulting from chemotherapy. Many stem cells exist within the body in a latent, inactive form ready to be activated by the proper molecular "switch".
Vitro Biopharma Launches New Products to Advance Breast Cancer Treatment
ACCESSWIRE - Tue May 03, 8:30AM CDT
GOLDEN, CO / ACCESSWIRE / May 3, 2016 / Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the launch of breast cancer CAFs (cancer-associated fibroblasts) that provide additional tools for drug discovery in the quest to eradicate cancer. CAFs reside within tumor tissue and serve various functions including suppression of immune responses to cancerous cells, support of tumor cell growth and enhancement of metastasis. Modern immunotherapy has evolved into CAR-T technology (chimeric antigen receptor T cells) whereby patient's immune cells are genetically engineered to migrate to, attach to and eliminate cancer cells. Several biotech firms are developing CAR-T cancer immunotherapeutic products including Juno Therapeutics, Kite Pharma and Ziopharm Oncology. Some early trials for treatment of leukemia show nearly complete remission using this therapy. However, CAFs present within solid tumors continue to block engineered T cells and require intervention to maximize immunotherapy to completely eradicate cancerous cells (PNAS 110: 20212, 2013).
KITE: 50.91 (-0.18), JUNO: 42.66 (-0.70)
CEO Letter to Shareholders: 2015 Results Expand Therapy Options for Concussion
ACCESSWIRE - Wed Nov 04, 12:13PM CST
GOLDEN, CO / ACCESSWIRE / November 4, 2015 /
Vitro Biopharma Launches New Bioanalytical Services and Novel Stem Cell-Derived Renal & Neural Cells
ACCESSWIRE - Tue Sep 22, 9:19AM CDT
GOLDEN, CO / ACCESSWIRE / September 22, 2015 / Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced expansion of its product/service offerings to include biomarker profiling services and stem cell derived neuronal and renal cells. Vitro Biopharma's new services include simultaneous determination of several molecules through multi-plexed assays. The cells of our bodies communicate with each other through the secretion of numerous bioactive substances that control fundamental physiological and pathological conditions. Our new services offer precise measurement of numerous different signaling molecules at once including cytokines, growth factors, hormones and other biological signaling molecules. We offer panels of biomarkers for analysis of the several organ systems and pathological states of the body: cancer, cardiovascular, immunology/inflammation, metabolism/endocrine, neurology and toxicology. Within each category we offer several panels of individual biomarker groups.
Vitro Biopharma Announces Advancement of its Traumatic Brain Injury Clinical Trial and a Favorable Ruling from the FDA
ACCESSWIRE - Wed Sep 02, 11:41AM CDT
GOLDEN, CO / ACCESSWIRE / September 2, 2015 / Vitro Diagnostics, Inc. (OTC: VODG), dba Vitro Biopharma, announced advances in clinical applications of its products and a favorable ruling by the FDA regarding this trial. The Company's phase I clinical trial consists of combining two previously FDA-approved drugs in a novel manner to treat TBI, including concussion, by regeneration of damaged cells through the activation of resident stem cells within the brain. TBI is a high incidence condition with few therapeutic options besides reduction of secondary injury and rehabilitation or physical therapy. Brain stem cells exist in only restricted parts of the brain but appear to be capable of regenerating cells of the brain when activated by the appropriate biological signal, in this case, a unique combination of drugs previously approved for other indications. While stem cell therapy is often achieved by stem cell transplants, it is also possible to activate stem cells by biological signaling agents that activate specific pathways resulting in stem cell proliferation, differentiation and migration. There are FDA-approved drugs used to stimulate red and white blood cell formation that have been used for decades now to treat patients undergoing chemotherapy and the resulting blood cell deficiencies. Other stem cell activating compounds are known and being developed.
Vitro Biopharma Launches MSC-derived Cardiac and Neural Cells for Pre-clinical Toxicology Testing
ACCESSWIRE - Tue Jun 02, 8:52AM CDT
GOLDEN, CO / ACCESSWIRE / June 2, 2015 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the commercial launch of cardiac and neural cells that are differentiated from human MSCs. Our new products include cardiomyocytes, alpha motor neurons and neural stem cells. In support of this commercial launch, we have also launched an improved and updated website featuring enhanced functionality and improved access to product information. Our newly developed cardiomyocytes and alpha motor neurons compliment existing stem cell-derived cells for use in cell-based assays of drug toxicity: MSC-derived osteoblasts and chondrocytes. Vitro Biopharma has additional cell types in development including dopaminergic neurons, proximal tubule epithelial cells and podocytes. The latter cells will enable cell-based assays for renal toxicity.
Alternatives to Stem Cell Transplants Supported by Key Medical Breakthroughs of 2014
ACCESSWIRE - Tue Jan 13, 9:18AM CST
GOLDEN, CO / ACCESSWIRE / January 13, 2015 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the growing scientific support for use of stem cells that reside within the body for therapeutic and performance enhancement. A key medical advance of 2014 was research published by scientists at Stanford University and Harvard University regarding mechanisms underlying "parabiosis", the well-known reversal of aging when young animal blood is transferred into older animals. This research, considered a key scientific advance of 2014, identified factors in blood that transform stem cells from an inactive, latent form to active cells that regenerate and replenish aging cells resulting in reversal of aging in animals. This newly identified factor, called growth-differentiation factor 11 (GDF11, or, BMP-11) adds to a growing list of endogenous biological agents that activate stem cells from quiescence to growth and differentiation. The well-known growth factors erythropoietin and G-CSF have been used as therapeutic agents for 25 years to treat anemia and immuno-suppression resulting from chemotherapy. Many stem cells exist within the body in a latent, inactive form ready to be activated by the proper molecular "switch".
